BRIEF-ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS

Reuters
Dec 01
BRIEF-ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS

Dec 1 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A:

  • ACTINIUM PHARMACEUTICALS ANNOUNCES ATNM-400 DATA DEMONSTRATING POTENT EFFICACY IN TRIPLE-NEGATIVE BREAST CANCER AND ABILITY TO OVERCOME ENDOCRINE AND HER2-TARGETED THERAPY RESISTANCE BEING PRESENTED AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Source text: ID:nPn9zdYBTa

Further company coverage: ATNM.A

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10